Helicase Venture

www.helicaseventure.com

VCMatch tracks Helicase Venture as an investor focused on AI/ML, Biotech, and Data Infrastructure companies, Pre-Seed and Seed rounds, and $1m to $5m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$1m to $5m

Stages

Pre-Seed, Seed, Series A

Focus Areas

AI/ML, Biotech, Data Infrastructure

Geography

Not specified

Investment Thesis

Helicase Venture is a science-first, early-stage investor that seeks to back teams using creative, novel approaches at the intersection of biology and computation. They focus on the earliest development phases (seed through early clinical/proof-of-concept) and act as active, hands-on partners—bringing domain expertise, scientific networks and advisor support to accelerate companies from bench to patients.

Is Helicase Venture right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Helicase Venture is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in AI/ML, Biotech, Data Infrastructure, and Enterprise SaaS, with public check-size signals around $1m to $5m.

Focus statement

They invest in early-stage life sciences and Bio‑IT (engineering health / AI companies), with key interests in synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and technologies or tools that reduce healthcare development costs. Typical initial checks are $1–5M into seed and Series A opportunities.

Value Add

Explicit Bio‑IT focus: they position themselves at the biology + computation nexus rather than general tech or pure biotech investors ("life science and Biology and computational powered technologies").
Stage specialization: preference for the earliest stages — "Stage and Phase: The Earlier the Better" and investments from pre‑clinical through early clinical proof of concept.
Science expertise on the team: emphasize deep scientific understanding and operational experience across drug discovery and development ("We understand the science. From bench to patients to the boardroom, our team has experience across the field.").
Hands‑on, team-driven investment process: "Our investments are done as a team, with each member contributing their domain expertise" and they bring "a wide range of scientific networks and advisors."
Defined initial ticket size and commitment model: typically commit "$1-5M at initial investment" and describe themselves as "deeply committed investors."